Aprea Therapeutics reports FY2024 net loss $13M, cash $22.8M; APR-1051 data H2 2025

Aprea Therapeutics, Inc.

Net loss of $2.9M (Q4) and $13.0M (FY2024); cash $22.8M, sufficient into Q1 2026.
ACESOT-1051 trial of WEE1 inhibitor APR-1051 enrolling Cohort 5 (70 mg); open-label data expected H2 2025.
ABOYA-119 trial of ATR inhibitor ATRN-119 evaluating BID dosing at Dose Level 7; dose escalation completion H2 2025.
Employment agreement amended for officer John P. Hamill: severance extended to 12 months (18 months post-change-of-control).
R&D expense increased to $9.4M for FY2024 from $7.6M, driven by trial costs and personnel.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.